Want to see HK:6998 full AI Analyst Report?
6998 Stock Chart & Stats
HK$3.06
HK$0.04(2.16%)
At close: 4:00 PM EST
HK$3.06
HK$0.04(2.16%)
Day’s Range― - ―
52-Week RangeHK$1.48 - HK$5.60
Previous CloseN/A
Volume193.50K
Average Volume (3M)909.38K
Market Cap
HK$3.47B
Enterprise ValueHK$4.49K
Total Cash (Recent Filing)HK$1.06B
Total Debt (Recent Filing)HK$1.49B
Price to Earnings (P/E)6.3
Beta0.40
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.24
Shares Outstanding2,014,041,700
10 Day Avg. Volume879,300
30 Day Avg. Volume909,383
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.17
Price to Sales (P/S)1.67
P/FCF Ratio11.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
2025 Financial TurnaroundA clear 2025 earnings and revenue step-up indicates the company can scale commercial operations and convert sales into meaningful operating profit. This improves capacity to fund R&D, pursue partnerships and demonstrates the business model can generate durable earnings if execution is sustained over coming quarters.
Positive Free Cash FlowMaterial operating and free cash flow in 2025, with FCF near net income, improves internal funding for pipeline development and reduces near-term external finance needs. Strong cash conversion supports long-term investment, operational flexibility and resilience across funding cycles if maintained.
Biologics-focused Business ModelAn integrated biologics model—R&D through manufacturing—aligns with durable structural demand in oncology and autoimmune therapies. Vertical capabilities support faster development, cost control and partnering/out-licensing options, sustaining revenue diversity and long-term competitive positioning.
Bears Say
Revenue Volatility & Zero-Revenue YearsHistoric swings including multi-year losses and intermittent zero reported revenue undermine confidence in repeatable sales and make forecasting future margins risky. Durable valuation of assets and long-term planning is challenged if revenue consistency is not re-established.
Sharp Increase In DebtA rapid rise in leverage reduces balance sheet flexibility and increases refinancing and interest-rate exposure despite current moderate debt-to-equity. If cash generation weakens, servicing higher debt could constrain R&D spending and strategic initiatives over the medium term.
Inconsistent Returns & Historical LossesROE volatility and years of negative returns imply the 2025 profitability improvement may be cyclical or event-driven. Without sustained higher returns, shareholder capital recovery and long-term investment case remain uncertain, increasing execution risk for long-duration biotech projects.
Genor Biopharma Holdings Limited News
6998 FAQ
What was Genor Biopharma Holdings Limited’s price range in the past 12 months?
Genor Biopharma Holdings Limited lowest stock price was HK$1.48 and its highest was HK$5.60 in the past 12 months.
What is Genor Biopharma Holdings Limited’s market cap?
Genor Biopharma Holdings Limited’s market cap is HK$3.47B.
When is Genor Biopharma Holdings Limited’s upcoming earnings report date?
Genor Biopharma Holdings Limited’s upcoming earnings report date is Sep 02, 2026 which is in 21 days.
How were Genor Biopharma Holdings Limited’s earnings last quarter?
Genor Biopharma Holdings Limited released its earnings results on Mar 27, 2026. The company reported HK$0.375 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Genor Biopharma Holdings Limited overvalued?
According to Wall Street analysts Genor Biopharma Holdings Limited’s price is currently Overvalued.
Does Genor Biopharma Holdings Limited pay dividends?
Genor Biopharma Holdings Limited does not currently pay dividends.
What is Genor Biopharma Holdings Limited’s EPS estimate?
Genor Biopharma Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genor Biopharma Holdings Limited have?
Genor Biopharma Holdings Limited has 2,014,041,700 shares outstanding.
What happened to Genor Biopharma Holdings Limited’s price movement after its last earnings report?
Genor Biopharma Holdings Limited reported an EPS of HK$0.375 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.857%.
Which hedge fund is a major shareholder of Genor Biopharma Holdings Limited?
Currently, no hedge funds are holding shares in HK:6998
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genor Biopharma Holdings Limited
Genor Biopharma Holdings Limited operates as a biopharmaceutical enterprise, concentrating its efforts on the research, development, and commercialization of therapeutic agents for oncology and autoimmune disorders, both within China and globally. Its key investigational medicines include GB242, an infliximab (Remicade) biosimilar. This drug is purposed for the treatment of various conditions such as rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric Crohn's disease, and fistulizing Crohn's disease. Another prominent candidate is GB491 (lerociclib), an oral CDK4/6 inhibitor currently undergoing Phase III clinical trials for hormone receptor-positive (HR+)/HER2- breast cancer. Additionally, GB492, a stimulator of interferon genes (STING) agonist, is in Phase 1/2 clinical development, with expectations of synergistic effects when combined with GB226 for solid tumor treatment. The company's pipeline also encompasses GB221, a HER2 monoclonal antibody (mAb) designed to mimic trastuzumab (Herceptin); geptanolimab (GB226), a novel PD-1 mAb; GB223, a receptor activator of nuclear factor-B Ligand (RANKL) mAb, which is in Phase I clinical trials; and GB261, also in Phase I clinical trials for B-cell non-Hodgkin Lymphoma. Furthermore, its product candidates in clinical trials for cancer treatment include GB262, GB264, GB265, and GB266. Originally named JHBP (CY) Holdings Limited, the company adopted its current moniker, Genor Biopharma Holdings Limited, in June 2021. Founded in 2007, the firm maintains its headquarters in Shanghai, China.
Technical Analysis
Antengene Corporation Limited
―
Jacobio Pharmaceuticals Group Co., Ltd.
―
Mabpharm Limited
―
SinoMab Bioscience Ltd.
―
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
―